We designed and synthesized novel 2,3-disubstituted quinazolin-4(3H)-ones by microwave technique and characterized them by spectral analysis. Synthesized compounds were screened for cytotoxicity and for antiviral activity against influenza A (H1N1, H3N2 and H5N1), severe acute respiratory syndrome corona, dengue, yellow fever, Venezuelan equine encephalitis (VEE), Rift Valley fever, and Tacaribe viruses in cell culture. A neutral red uptake assay was used to determine 50% virus-inhibitory concentrations (EC 50 ) of test compounds and their 50% cytotoxicity concentration (CC 50 ) in uninfected Madin-Darby canine kidney, Vero, and Vero 76 cells; selectivity indices (ratio of CC 50 to EC 50 ) were derived from the data.
Introduction
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Quinazolin-4(3H)-one is a versatile lead molecule for the design of potential bioactive agents. 2,3-Disubstituted quinazolin-4(3H)-ones were reported to have anti-HIV (Shah et al., 1995; Desai et al., 1998; , anticancer (Raffa et al., 1999; Murugan et al., 2003; Girija et al., 2005) and antiviral (Manoj et al., 2001; Selvam et al., 2004; Pandey, 1996) properties. A large number of quinazolines have been synthesized and studied for wide range of antiviral activity, but the antiviral activities of quinazolines against respiratory and biodefense viruses has not been well explored. Based on these findings, some new 6-bromo/6,8-dibromo-2,3 disubstituted quinazolinones were synthesized and screened for antiviral activity against respiratory and biodefense viruses.
Anthranilic acid reaction with benzoyl chloride yielded 2-phenyl-1,3-benzoxazin-4-one by N-acylation via dehydrative cyclization. A series of some novel 2,3-disubstituted quinazolin-4(3H)-one derivatives were synthesized by condensation of the primary aromatic amino group of sulphonamide with 2-substituted-1,3-benzoxazine-4-one to afford 2,3-disubstituted quinazolin-4(3H)-one derivatives.
Materials and methods
Chemical analyses
Melting points were determined in open capillary tubes on a Thomas Hoover melting point apparatus and are uncorrected. IR spectra were recorded for KBr pellets on a Jasco-410 infrared spectrophotometer, 1 H-NMR spectra were determined on a BRUKER AMX 400 MHz with tetramethyl silane as an internal standard. The samples were dissolved in and the values measured in δ PPM. Microwave irradiation reaction was performed in a unmodified domestic microwave oven (LG; [LG Electronic corporation, New Delhi, India] single irradiation type input 220V 50 Hz, 980 W, 4.7 A; frequency 2,450 MHz).
Synthesis of 2-sulphonamide-3-substituted quinazolin-4(3H)-ones derivatives Equimolar (0.01) mixtures of benzoxazine and sulphonamides (sulphanilic acid, sulphanilamide, sulphadiazine, sulphadimidine and sulphamoxazole) were dissolved in glacial acetic acid. The reaction uses the microwave irradiation in an unmodified domestic microwave oven at 80% intensity with 30 s/cycle for 3 min and set aside. The resultant solid was washed with dilute ethanol, dried and recrystallized from an ethanol-chloroform mixture. Physical and spectral data of the synthesized compounds was presented in supplementary file (see Additional files).
Antiviral and cytotoxicity assays
Synthesized compounds were screened for antiviral activity against influenza A/New Caledonia/20/99 (H1N1), influenza A/California 7/04 (H3N2), influenza A/Vietnam/1203/04 (H5N1) × A/Ann Arbor/6/60 (a hybrid virus containing the A/Ann Arbor H1N1 virus core and the haemagglutinin and neuraminidase from A/Vietnam), SARS corona (Urbani strain), dengue type 2 (New Guinea C strain), yellow fever (17D vaccine strain), Venezuelan equine encephalitis (VEE, TC-83 vaccine strain), Rift Valley fever (RVF, MP-12 vaccine strain) and Tacaribe (TRVL 11573 strain) viruses in cell culture by cytopathic effect inhibition assays quantified by a neutral red dye uptake assay (Smee et al., 2001; Selvam et al., 2006; Gowen et al., 2007) . Sources of viruses were as follows: the three influenza viruses and SARS coronavirus from the Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA), dengue from CDC (Ft. Collins, CO, USA), RVF from Robert Tesh (World Reference Centre for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, TX, USA), Tacaribe and yellow fever viruses from the American Type Culture Collection (ATCC, Manassas, VA, USA), and VEE from the US Army Medical Research Institute of Infectious Diseases (USAMRIID, Ft. Detrick, Frederick, MD, USA). Madin-Darby canine kidney (MDCK) cells were used for assaying influenza viruses. Vero 76 cells were used to assay SARS corona, RVF and Tacaribe viruses. The other viruses were assayed in Vero cells. All cell lines were purchased from ATCC. Antiviral assays were performed in 96-well microplates of cells infected with approximately 50-100 cell culture infectious doses of virus. Plates were evaluated after virus destroyed the untreated cells, which varied with the type of virus as follows: influenza (3 days), SARS corona (4 days), dengue (10 days), yellow fever (6 days), VEE (3 days), SARS corona (4 days), RVF (3 days) and Tacaribe (7 days). Cytotoxicity of the test compounds was determined in parallel in uninfected MDCK, Vero, and Vero 76 cells by neutral red uptake assay (Smee et al., 2001 ) using stationary monolayers of cells.
Positive control compounds were included with each assay for comparative purposes. Ribavirin (used for influenza, Tacaribe and RVF virus assays) was obtained from ICN Pharmaceuticals (Costa Mesa, CA, USA). Compound M128537, a protease inhibitor (used for SARS coronavirus assays), was obtained from Sui Cai (Maxim Pharmaceuticals, San Diego, CA, USA), Interferon alfacon-1 (used for dengue, yellow fever, and VEE virus assays) was provided by Larry Blatt (InterMune, Inc., Brisbane, CA, USA).
Results
Synthesis of quinazolinones
Fifteen compounds were prepared by microwave method (Figure 1 ), the synthesis of each being rapid and convenient. The physical and spectral data of the purified compounds are presented in Table 1 . Yields of compounds ranged from 50 to 80%.
Antiviral activities of compounds
The compounds were evaluated for antiviral activity against influenza A (H1N1, H3N2, and H5N1) viruses in cell culture (Table 1) . The majority of compounds tested were not active or very weakly active, having selectivity index (SI) values <3. Moderate antiviral activity was seen with three compounds against the H5N1 virus, namely compound 5, compound 10 and compound 15. Compound 10 was also inhibitory to influenza H1N1 virus. The positive control compound ribavirin was evaluated in parallel. Ribavirin exhibited SI values of 17-27 against the three influenza virus strains. Thus, the antiviral selectivities of the test compounds (5, 10 and 15) were not as good as that of ribavirin.
The quinazolinones were further evaluated against a broader panel of viruses, including the SARS corona respiratory virus and five biodefense viruses (Table 2) . Compound 5 (SPS-II) showed activity against VEE, Tacaribe and RVF viruses. Some cytotoxicity, however, was also seen with this compound, which varied with the cell line used for assay. Compound 4 inhibited VEE virus below the cytotoxic concentration, but was not as potent as 5. The rest of the other compounds were considered inactive or weakly active. The positive control compound interferon alfacon-1 was inhibitory to VEE virus at <0.1 μg/ml. Ribavirin inhibited Tacaribe and RVF viruses at 4.2 and 15 μg/ml, respectively. SARS corona, dengue, and yellow fever viruses were not inhibited by any of the compounds. Activity was seen by the positive control compound M128537 against SARS coronavirus at 28 μg/ml.
Interferon alfacon-1 inhibited dengue and yellow fever viruses at <0.1 μg/ml. Most of the quinazolinones were not cytotoxic (CC 50 >100 μg/ml; Tables 1 and 2 ).
Discussion
We have previously reported the antiviral activity of novel quinazolinones against vaccinia virus, and many of these compounds also exhibited marked cytostatic properties in lymphocytes (Selvam et al., 2003) . Though a variety of quinazoline derivatives have been synthesized and studied for wide range of antiviral activity, the antiviral activities of quinazolines against respiratory and biodefense viruses have not been extensively explored. In this study we synthesized 15 derivatives of quinazolinones and evaluated them for antiviral activity against respiratory and biodefense viruses.
The compounds 4 and 5 inhibited the replication of VEE virus below the cytotoxic concentration. Substitution in the SO 2 NH 2 group of SPS lead abolished the antiviral activity, indicating that the free group SO 2 NH 2 is essential for antiviral activity against VEE. Two newly synthesized compounds (5 and 15) effectively inhibited the replication of the H5N1 strain of influenza virus. These lead molecules are suitable for designing newer derivatives against avian influenza (H5N1) and Venezuelan Equine encephalitis virus, based upon the promising antiviral activity seen.
Recently we reported the activities of certain benzenesulphonamides against influenza viruses in cell culture (Selvam et al., 2006) . The potencies of some of them exceeded those of the present quinazolinone series. The compounds were found to inhibit virus replication as a result of interfering with virus adsorption. Those compounds and the present ones share similarity in having a modified sulphur group on them, suggesting they may have a common mode of action. Further work will need to be done to explore this possibility.
There is a need to discover new compounds that are inhibitory to influenza viruses due to the emergence of potentially pandemic virus strains and viral resistance against approved drugs. The methodology reported here allows for rapid synthesis of a number of quinazolinone derivatives that can be tested for anti-influenza virus activity, as well as for activity against other viruses of concern to the medical community. 
